On May 26, 2020, Innovation Pharma reported receiving data from a leading public health research institute showing Brilacidin inhibits SARS-CoV-2, the novel coronavirus responsible for COVID-19, in a human cell line. Brilacidin, in comparison to vehicle control, exhibited an inhibitory effect on SARS-CoV-2 in a dose-dependent mannerﾗan average 29 percent inhibition at 0.1ug/ml (the lowest concentration) to an 85 percent inhibition at 100ug/ml (the highest concentration). Brilacidin is one of the few drugs targeting COVID-19 that has been tested in phase 2 human trials for other clinical indications, providing an established safety and efficacy profile.